Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Biogen has turned to M&A to offset its recent troubles with pipeline failures and aborted product launches, agreeing to a $7.3 billion deal to acquire Reata Pharma. The $172.50-per-share cash deal ...

Find the latest Ionis Pharmaceuticals, Inc. (IONS) stock quote, history, news and other vital information to help you with your stock trading and investing.